Patient choice in clinical trials.
D000818:Animals; D017322:Clinical Trials, Phase II as Topic; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use*; D051100:Glial Cell Line-Derived Neurotrophic Factor; D000882:Haplorhini; D006801:Humans; D007603:Jurisprudence; D009414:Nerve Growth Factors / Q000009:adverse effects / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D009518:New York; D010300:Parkinson Disease / Q000188:drug therapy*; D017060:Patient Satisfaction; D035842:Research Subjects
D015507:Drugs, Investigational; C495039:GDNF protein, human; D051100:Glial Cell Line-Derived Neurotrophic Factor; D009414:Nerve Growth Factors; D018696:Neuroprotective Agents